Literature DB >> 1863404

Cellular profiles in bronchoalveolar lavage fluid of HIV-infected patients with pulmonary symptoms: relation to diagnosis and prognosis.

B N Jensen1, I M Lisse, J Gerstoft, S Borgeskov, P Skinhøj.   

Abstract

Bronchoalveolar lavage (BAL) cell differentials and T-lymphocyte subpopulations were analysed in 95 HIV-infected patients with pulmonary symptoms to determine whether the type of cellular inflammatory response could be useful in diagnosis or as a prognostic marker. Patients with Pneumocystis carinii pneumonia (PCP) had more BAL fluid lymphocytes, mainly comprising CD8+ cells, and patients with bacterial infection had more neutrophils than other patients. Neither of these changes were mirrored in peripheral blood. Seven patients who died after their acute episode of PCP had significantly higher BAL fluid neutrophils than 53 patients with PCP who survived (P = 0.002). There seems to be correlation between BAL fluid neutrophilia, PCP and concomitant bacterial infection since four out of seven patients with a fatal outcome had coinfection with bacteria, whereas only one patient with PCP and bacterial coinfection survived (P = 0.0007).

Entities:  

Mesh:

Year:  1991        PMID: 1863404     DOI: 10.1097/00002030-199105000-00008

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

Review 1.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

2.  Does analysis of bronchoalveolar lavage fluid provide a tool to monitor disease progression or to predict survival in patients with HIV-1 infection?

Authors:  C Agostini; G Semenzato
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139

3.  Neither classical nor alternative macrophage activation is required for Pneumocystis clearance during immune reconstitution inflammatory syndrome.

Authors:  Zhuo-Qian Zhang; Jing Wang; Zachary Hoy; Achsah Keegan; Samir Bhagwat; Francis Gigliotti; Terry W Wright
Journal:  Infect Immun       Date:  2015-09-14       Impact factor: 3.441

4.  Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia.

Authors:  Jing Wang; Francis Gigliotti; Samir P Bhagwat; Thaddeus C George; Terry W Wright
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

5.  Immune Modulation as Adjunctive Therapy for Pneumocystis pneumonia.

Authors:  Jing Wang; Terry W Wright; Francis Gigliotti
Journal:  Interdiscip Perspect Infect Dis       Date:  2011-08-29

6.  Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study.

Authors:  Benjamin Jean Gaborit; Benoit Tessoulin; Rose-Anne Lavergne; Florent Morio; Christine Sagan; Emmanuel Canet; Raphael Lecomte; Paul Leturnier; Colin Deschanvres; Lydie Khatchatourian; Nathalie Asseray; Charlotte Garret; Michael Vourch; Delphine Marest; François Raffi; David Boutoille; Jean Reignier
Journal:  Ann Intensive Care       Date:  2019-11-27       Impact factor: 6.925

Review 7.  Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments.

Authors:  Aaron D Gingerich; Karen A Norris; Jarrod J Mousa
Journal:  Pathogens       Date:  2021-02-19

8.  Prognostic implication of bronchoalveolar lavage fluid analysis in patients with Pneumocystis jirovecii pneumonia without human immunodeficiency virus infection.

Authors:  Chiwook Chung; Chae Man Lim; Yeon-Mok Oh; Sang Bum Hong; Chang-Min Choi; Jin Won Huh; Sei Won Lee; Jae Seung Lee; Kyung-Wook Jo; Wonjun Ji; Chan-Jeoung Park; Mina Kim; Heungsup Sung; Young-Uk Cho; Hyo Sin Cho; Ho Cheol Kim
Journal:  BMC Pulm Med       Date:  2022-06-26       Impact factor: 3.320

9.  Massive Cavitation by Pneumocystis jirovecii in an Immunocompromised Patient.

Authors:  Aldair Chaar-Hernandez; Jorge Montes; Maria C Rojas; Diego A Padilla-Mantilla; Abdelilah Lahmar; Juan F Toledo-Martinez; Francisco J Somoza-Cano
Journal:  Cureus       Date:  2022-05-26

10.  Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia.

Authors:  Tark Kim; Heungsup Sung; Yong Pil Chong; Sung Han Kim; Eun Ju Choo; Sang Ho Choi; Tae Hyong Kim; Jun Hee Woo; Yang Soo Kim; Sang Oh Lee
Journal:  Infect Chemother       Date:  2018-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.